Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.

Inclusion Criteria: * Age18-65 years (inclusive of 18 and 65), no restriction on gender; * HBsAg positive history for at least 6 months; * Family history of liver cancer \[including first-degree and second-degree relatives; first-degree relatives are parents, children, and siblings (same parents), while second-degree relatives are uncles, aunts, grandparents, and great-grandparents; a family history of liver cancer means that one or more first-degree or second-degree relatives have had liver cancer\]; * Planning to or already receiving treatment with Peginterferon alpha-2b in combination with nucleoside (acid) analogs, or receiving nucleoside (acid) analogs treatment alone; * Negative urine or serum pregnancy test within 24 hours before the first dose (for women of childbearing age); * Willing to receive treatment and sign an informed consent form. Exclusion Criteria: * Allergy to interferon; * History of using telbivudine for antiviral treatment; * ALT(Alanine Aminotransferase) greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal; * Decompensated liver cirrhosis; * Neutrophil count \< 1.5 x 10\^9/L or platelet count \< 80 x 10\^9/L; * Presence of severe lesions in vital organs such as the cardiovascular, pulmonary, renal, brain, and fundus; * Those with autoimmune diseases, psychiatric disorders, poorly controlled diabetes, or thyroid dysfunction (hyperthyroidism or hypothyroidism); * Confirmed or suspected liver cancer or other malignant tumors; * Post-organ transplant or preparing for organ transplantation; * Currently using immunosuppressants; * Pregnant or planning to become pregnant within 2 years; * Alcohol or drug addicts; * HIV co-infection; * Other conditions deemed unsuitable for interferon use by the attending physician.